For the last 5 years, PSMA-binding ligands labelled with the β-particle-emitter 177Lu have been used in an increasing number of medical centres worldwide for the treatment of metastatic castration-resistant prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.